Axillary Management in Breast Cancer: De-escalation Principles
Introduction to De-escalation
- The American College of Radiology recommends tailoring axillary management in breast cancer to tumor biology, nodal burden, and response to therapy, with minimization or omission of axillary surgery in carefully selected patients to reduce morbidity without compromising oncologic outcomes 1, 2
- De-escalation aims to minimize morbidity, such as lymphedema, pain, stiffness, and sensory loss, while maintaining excellent oncologic outcomes, as supported by the American College of Radiology and Annals of Oncology 1, 3
Management of Clinically Node-Negative Patients
- The American College of Radiology and Journal of Clinical Oncology suggest that low-risk patients, such as those with age ≥50 years, grade 1-2, HR+/HER2-, T1-T2 tumors (≤5 cm) with breast conservation planned, may avoid axillary surgery altogether 5, 1
- Sentinel lymph node biopsy (SLNB) remains the standard of care for most clinically node-negative patients, according to Annals of Oncology 3, 6
Management of Node-Positive Patients
- The American College of Radiology and Journal of Clinical Oncology recommend that axillary lymph node dissection (ALND) can be safely omitted in patients with 1-2 positive SLNs who are undergoing breast-conserving surgery with planned whole breast radiation 2, 5
- Regional nodal irradiation (RNI) is a valid alternative to ALND in patients with positive SLNs, as supported by Annals of Oncology 6
Role of Axillary Radiotherapy
- Axillary radiation is a valid alternative to ALND in patients with positive SLNs, according to Annals of Oncology 6
Diagnostic Considerations
- Preoperative axillary ultrasound has variable sensitivity (52-90%) and should not be the sole determinant for axillary management, as noted by the Journal of the American College of Radiology 1, 7
- After neoadjuvant therapy, SLNB has better accuracy when using dual tracer technique and removing at least 3 sentinel nodes, as recommended by the Journal of the American College of Radiology and Annals of Oncology 8, 4